Compare Unity Software Inc (U) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Unity Software Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Unity Software Inc trades at $42.48 (market cap $18.81B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 7.1× Unity Software Inc's market cap. Which is the better fit depends on your goals.
| U | VRTX | |
|---|---|---|
Market Cap | $18.81B | $134.06B |
Sector | Technology | Health |
52-Week High | $49.47 | $557.96 |
52-Week Low | $17.13 | $376.62 |
Enterprise Value | $18.70B | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Unity Software (U) trades at $42.75, up 2.62% with bullish technical signals and strong analyst support. The company shows improving fundamentals with revenue stabilizing around $1.8B and narrowing losses, though still reporting negative net income. Recent Q2 2026 earnings beat expectations, while institutional activity shows mixed positioning with some major funds increasing stakes. Technical indicators suggest bullish momentum with support at $41 and resistance at $44.
The outlook remains cautiously optimistic with 81% analyst buy ratings and $47.45 price target, representing 11% upside. Key opportunities include Vector platform growth and margin expansion, while risks center on sustained profitability challenges and competitive pressures in the gaming/ad tech space. Execution on strategic initiatives will be critical for stock performance.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
